Eiko Lifesciences Ltd — Important, 25-05-2026: Company Update

Eiko LifeSciences submitted its Annual Secretarial Compliance Report for the financial year, generally confirming its compliance with various investor-protection rules. However, SEBI imposed a penalty of Rs. 0.01 Cr on a Promoter Group Entity for not disclosing margin pledge transactions that occurred between 2019 and 2021, as required by rules governing significant share acquisitions. Separately, the company also confirmed the proper maintenance of its Structured Digital Database for insider trading information, capturing all required events during the year with no non-compliance, indicating robust internal controls for price-sensitive information.